Alnylam Pharma (ALNY) Announces Initiaition of ALN-AT3 Phase 1 in Hemophilia
Tweet Send to a Friend
Alnylam Pharma (NASDAQ: ALNY) announced today that it has initiated a Phase 1 open-label extension (OLE) study with ALN-AT3, a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
